Contact Us

ECMC Trial Portfolio

Select Disease Group:


All Solid Tumours

Project Title Website PI Recruitment Contact


A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors


Disposition of[14C]Pamiparib in Patients with Tumours Prof D Palmer 3 Send E-mail


An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors


REPLIMUNE Dr J Sacco 4 Send E-mail


Back to top




Project Title Website PI Recruitment Contact


A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening


plasmaMATCH Prof C Palmieri 7 Send E-mail


Back to top




Project Title Website PI Recruitment Contact


AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)


AVAIL-T Dr. A. Arumainathan 1 Send E-mail


Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with faEcal microbiota transfer (HERACLES)


HERACLES Dr. A. Patel 0 Send E-mail


A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.


PHAZAR Dr. A. Patel 1 Send E-mail


RomiCar - Phase I/II study to determine the maximum tolerated dose and overall response rate of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma


RomiCAR Dr. N . Kalakonda 1 Send E-mail


Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)


TIDaL Dr A. Arumainathan 2 Send E-mail


Back to top


Head & Neck

Project Title Website PI Recruitment Contact


Cambridge Brain Mets Trial 1: A proof­ of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low­-dose, targeted radiotherapy


CamBMT1 Dr B Haylock 0 Send E-mail


NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer


NICO Dr A Haridass 0 Send E-mail


A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer


WISTERIA: WEE1 inhibitor with Cisplatin and Radiotherapy Dr J Sacco 1 Send E-mail


Back to top



HPB / Upper GI

Project Title Website PI Recruitment Contact


ACIT I: A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients


ACIT-1 Prof. D Palmer 23 Send E-mail


OUTREACH: A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)


OUTREACH / CANC 4818 Prof. D Palmer 5 Send E-mail


Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma


Phase 1-2 Study of ADI plus FOLFOX in GI cancer focusing on HCC Prof. D Palmer 0 Send E-mail


Back to top



Project Title Website PI Recruitment Contact


The Cancer Research UK Stratified Medicine Programme: Pilot Study


CR UK Stratified Medicine Pilot study Dr. Carles Escriu 59 Send E-mail


Back to top



Project Title Website PI Recruitment Contact


A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma


Circulating tumour DNA guided therapy switch (CAcTUS) Dr. Shien Chow 0 Send E-mail


Back to top